Cell MedX Corp. provides additional information on its observational clinical trial with diabetes and related conditions
Carson City, Nevada--(Newsfile Corp. - January 30, 2018) - Cell MedX Corp. (OTCQB: CMXC) (9CX: MUN), ("Cell MedX" or the "Company"), is an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness. As reported in a news releases issued by the Company on January 24, 2018, an observational clinical trial was completed by Dr. Richard Tytus and his team at Hamilton Medical...
2018-01-30 8:00 AM EST
Cell MedX Corp. Assigned Legal Entity Identifier Number by Deutsche Börse Group
Carson City, Nevada--(Newsfile Corp. - January 29, 2018) - Cell MedX Corp. (OTCQB: CMXC) (9CX:MUN), ("Cell MedX" or the "Company"), announces that it has been assigned a Legal Entity Identifier number 967600RJ7LKTH79OWE67. About the Legal Entity Identifier Number ("LEI")The European Union has adopted regulations that require use of the LEI as a barcode equivalent aimed at pinpointing systemic risks. The LEI is a 20-digit alphanumeric code that is an internationally standardized and globally...
2018-01-29 8:00 AM EST
Cell MedX Corp. completes its first observational clinical trial and observes positive results with diabetes and related conditions
Carson City, Nevada--(Newsfile Corp. - January 24, 2018) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the observational clinical trial carried out by Dr. Richard Tytus and his team at Hamilton Medical Research Group in Hamilton, Ontario (the "Trial") has been...
2018-01-24 8:00 AM EST
Cell MedX Corp. Appoints Dr. Terrance Owen as CEO and Director
Carson City, Nevada--(Newsfile Corp. - December 5, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that it has appointed Dr. Terrance Owen to the Board of Directors and as Chief Executive Officer. Dr. Owen replaces Mr. McEnulty, as CEO of the Company. Mr. McEnulty will...
2017-12-05 8:00 AM EST
Cell MedX Corp. Closes the First Tranche of Its Non-Brokered Private Placement Financing, Converts Debt
Carson City, Nevada--(Newsfile Corp. - October 19, 2017) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that on October 12, 2017, the Company closed the first tranche of its non-brokered private placement offering (the "Offering") at a price of $0.25 per unit (the "Unit"), by...
2017-10-19 8:00 AM EDT
Cell MedX Corp. Provides Corporate Update
Carson City, Nevada--(Newsfile Corp. - August 31, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to provide its shareholders with the corporate update on its current operations. Private PlacementThe Company's board of directors has approved a private placement offering of up to...
2017-08-31 8:00 AM EDT
Cell MedX Corp. Provides Update on its Clinical Observational Trial
Carson City, Nevada--(Newsfile Corp. - July 31, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to announce that all 30 subjects taking part in the Company's ongoing clinical observational trial carried out by Dr. Tytus and his team at Hamilton Medical Research Group (the "Trial")...
2017-07-31 8:00 AM EDT
Cell MedX Corp. Provides Corporate Update
Carson City, Nevada--(Newsfile Corp. - July 5, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to announce that its currently ongoing clinical observational trial carried out by Dr. Tytus and his team at Hamilton Medical Research Group (the "Trial") is nearing its completion. To...
2017-07-05 5:00 AM EDT
Cell MedX Corp. Moves its Manufacturing to British Columbia, Canada
Carson City, Nevada--(Newsfile Corp. - April 26, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), is pleased to announce that the Company's Canadian subsidiary has entered into a production agreement with an ISO 9001 certified manufacturing facility in Coquitlam, BC, and selected North American suppliers for sourcing essential components for its eBalance Pro device. The move is intended to allow the Company to facilitate its planned distribution under the current...
2017-04-26 8:00 AM EDT
Cell MedX Corp. Announces FDA Registration and Update on Clinical Observational Study
Carson City, Nevada--(Newsfile Corp. - March 28, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), announced that it has completed its registration process with U.S. Food and Drug Administration ("FDA") and has initiated an application process to receive FDA clearance for use of its eBalance device as Class II non-exempt device. The Company is also pleased to announce that its ongoing clinical observational trial (the "Trial') is progressing as expected, and as of March...
2017-03-28 8:00 AM EDT
Cell MedX Corp. Announces First Subjects Screened and Qualified for the Observational Clinical Trial
Carson City, Nevada--(Newsfile Corp. - March 9, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), is pleased to announce that Dr. Richard Tytus, the Lead Investigator on the previously announced Observational Clinical Trial (the "Trial"), and his team at Hamilton Medical Research Group have commenced screening for qualified subjects. The group of seven potential study participants have been screened with an additional five subjects scheduled for screening. Three subjects...
2017-03-09 8:00 AM EST
Cell MedX Corp. Receives Approval from Ethics Review Board to Commence its Observational Clinical Trial in Canada for Type 1 and Type 2 Diabetics
Carson City, Nevada--(Newsfile Corp. - March 1, 2017) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), is happy to announce that it has received an approval from the Ethics Review Board to commence its observational clinical trial in Canada.As previously announced in the Company's news releases dated March 22, 2016, July 13, 2016, and January 23, 2017, Cell MedX has engaged Nutrasource Diagnostics Inc. ("NDI") to launch the observational clinical trial...
2017-03-01 8:00 AM EST
Cell MedX Corp. Engages Think Ink Marketing
Carson City, Nevada--(Newsfile Corp. - February 24, 2017) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that, it has retained Think Ink Marketing Data & Email Services, Inc. ("Think Ink") to develop an investor outreach program. The Company agreed to pay Think Ink a one-time fee of...
2017-02-24 4:52 PM EST
Cell MedX Corp. Moves Forward on Strategic Planning
Carson City, Nevada--(Newsfile Corp. - January 30, 2017) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that, in its efforts to better concentrate on upcoming observational clinical studies while simultaneously continuing the development of eBalance devices, the Company decided to...
2017-01-30 2:28 PM EST
Cell MedX Corp. Receives Approval from Health Canada to Commence its Observational Clinical Trial in Canada
Carson City, Nevada--(Newsfile Corp. - January 23, 2017) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), is happy to announce that it has received an approval from Health Canada to commence its observational clinical trial in Canada.As previously announced in the Company's news releases dated March 22, 2016 and July 13, 2016, Cell MedX has engaged Nutrasource Diagnostics Inc. ("NDI") to launch the observational clinical trial of its innovative and proprietary...
2017-01-23 7:30 AM EST
Cell MedX Corp. Receives Data from Observational Trials in Manilla, Philippines
Carson City, Nevada--(Newsfile Corp. - January 10, 2017) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), announces that it has received more positive observational results from our distributor, Mr. Greg Pek, in Manilla, Philippines. Mr. Greg Pek has been conducting observational trials with the supervision of Dr. Caballeros over the past five months and has recently added Mr. Cesar Diones, a Physiotherapist, to assist in expanding the trials. There are...
2017-01-10 7:30 AM EST
Cell MedX Corp. Receives First Commercial eBalance Pro Wellness Devices
Carson City, Nevada--(Newsfile Corp. - January 9, 2017) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), is pleased to announce that it has received its first eBalance Pro wellness devices ready for commercial distribution. These wellness devices are designed to promote general wellness and alleviate pain caused by chronic conditions such as: sciatica, neuropathy and arthritic pain.The eBalance Pro wellness device is an all-in-one, portable and fully automated...
2017-01-09 7:30 AM EST
Cell MedX Corp. Engages Tamarack Advisors
Las Vegas, Nevada--(Newsfile Corp. - November 8, 2016) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a development stage company focused on the commercialization of therapeutic devices for patients living with diseases such as diabetes, is pleased to announce that it has retained Tamarack Advisors Inc. ("Tamarack") to develop an investor communication and outreach program. The Company agreed to pay Tamarack at a rate of $10,000 per month for a period of three months for its...
2016-11-08 6:49 PM EST
Cell MedX Corp. Closes its Non-brokered Private Placement Financing
Las Vegas, Nevada--(Newsfile Corp. - October 13, 2016) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company") a development stage company focused on the commercialization of therapeutic devices for patients living with diseases such as diabetes, is pleased to announce that on October 12, 2016, the Company closed a non-brokered private placement offering (the "Offering") at a price of $0.15 per Unit, by issuing 9,094,605 Units for total gross proceeds of $1,364,191. Each Unit sold...
2016-10-13 4:37 PM EDT